|Print Page Close Window|
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).
05/19/17AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of First-Line Renal Cell CarcinomaRead More
05/16/17AVEO Announces Appointment of Matthew Dallas as Chief Financial OfficerRead More
05/15/17AVEO Issues Statement Regarding the Passing of Lead Director Henri A. TermeerRead More
02/13/17 8:30 a.m. ET AVEO Oncology at the 19th Annual BIO CEO & Investor Conference
Corporate PresentationAVEO Oncology Corporate Presentation